title: Treatment of Helicobacter pylori Infection 2015.
abstract: Many interesting articles have been published from many parts of the world over the last year assessing different issues around Helicobacter pylori eradication therapy. This article will address the published literature over the last year pertaining to the topic of treatment of H. pylori infection. The main themes that emerge are assessing the efficacy of standard triple therapy, as well as exploring new first-line treatments, mainly optimized nonbismuth- and bismuth-containing quadruple therapies with some promising data also emerging on dual therapy. There was also considerable progress in investigating antibiotic resistance rates with much more data emerging from varied parts of the world compared to recent years. There have also been advances in the use of adjunctive therapies, especially probiotic therapies. Undoubtedly, the eradication of H. pylori remains a worthwhile goal to alleviate the burden of diseases caused by the complications of this infection, including dyspepsia, peptic ulcer disease, and gastric cancer.
authors.affiliation: Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
authors.forename: Anthony
authors.initials: A
authors.lastname: O'Connor
authors.affiliation: Department of Gastroenterology, Instituto de Investigación Sanitaria Princesa (IIS-IP), Hospital Universitario de la Princesa, Madrid, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
authors.forename: Javier P
authors.initials: JP
authors.lastname: Gisbert
authors.affiliation: Department of Gastroenterology, Tallaght Hospital/Trinity College Dublin, Dublin, Ireland.
authors.forename: Colm
authors.initials: C
authors.lastname: O'Morain
authors.affiliation: Department of Medicine & Gastroenterology, Medical School, "Laiko" University General Hospital of Athens, University of Athens, Athens, Greece.
authors.forename: Spiros
authors.initials: S
authors.lastname: Ladas
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination / Q000379:methods; D014943:Global Health; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D019936:Probiotics / Q000008:administration & dosage
chemical_list: D000900:Anti-Bacterial Agents
keywords: antimicrobial susceptibility testing; compliance; first line; peptic ulcer disease; resistance; second line